AMICUS THERAPEUTICS,INC. (NASDAQ:FOLD) Files An 8-K Other EventsItem 8.01. Other Events.
On September21, 2017, Amicus Therapeutics,Inc. (the “Company”) issued a press release announcing that the U.S. FDA granted Orphan Drug Designation for ATB200/AT2221 for Pompe Disease. A copy of this press release is attached hereto as Exhibit99.1.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits: The ExhibitIndex annexed hereto is incorporated herein by reference.
Exhibit No. |
Description |
99.1 |
Press Release dated September21, 2017 titled “U.S. FDA Grants Orphan Drug Designation for ATB200/AT2221 for Pompe Disease.” |